It will take off well before they get to phase 3. They are in the process of launching phase 1. The players involved here developed FDA approved Quadramet. The new drug CycloSam bone cancer drug will improve upon this platform. Same doctors developing CycloSam for QSAM that developed Quadramet. This should fast track through approval process. Current market cap is just ~$15M. Compare this to the cap of other companies with drugs in the approval process. Very strong leadership team.